- June 5, 2014“Plausibility” and the Non-Conspiracy Elements of Antitrust Claims
- June 4, 2014NY Insurance Cases Cut Back Consequential Damages Claims
- June 2, 2014Food, the FTC and the Risks of Social Media Promotions
- June 2014Experts Rule in Rare Patent Owner IPR Wins
- May 28, 2014Jumping into the Actavis Briar Patch—Insight into How Courts May Structure Reverse Payment Antitrust Proceedings and the Questions That Actavis Left Unanswered
- May 21, 2014Insuring Against Many, But Not All, Risks: An Overview of the All Risk Policy
- March 24, 2014Avoiding Litigation: What Every Growing Company Should Know Now—Before it is Too Late
- May 15, 2014U.S. Patent Trial and Appeal Board Decisions: Secondary Considerations of Non-Obviousness—More On the Likelihood of Getting Discovery
- May 15, 2014Perfecting an Appeal: Intent Matters
- May 14, 2014Consumer Alert: FDA Warns Power Morcellators May Spread Cancer
- May 13, 20145 Red Flags In Pharmaceutical Settlements
- May 9, 2014Big Data, Price Intelligence and Antitrust
- Clones Not Patent-Eligible?
- May 8, 2014Three Reasons PTAB Litigation Costs More than We Thought
- May 5, 2014Claims Without Merit Are the Problem, Not Trolls
- May 2, 2014Carrying Your Umbrella When Navigating the Cloud
- May 1, 2014Matching Colors And Policies: Insurers May Be On The Hook
- May 2014No Surprises at Trial: Authentication, Best Evidence Rule and Admissibility of Expert Testimony
- April 28, 2014U.S. Patent Trial and Appeal Board Decisions: Secondary Considerations of Non-Obviousness—What Is the Likelihood of Getting Discovery?
- April 25, 2014The FDA’s “Natural” Reluctance: What it Means for Class Action Lawsuits
- April 25, 2014Personalized Medicine and Patent Eligibility under 35 U.S.C. § 101
- April 25, 2014Big Data, Social Media, and IP: How to Make “Likes,” “Tweets,” and “+1’s” Your Trade Secrets
- April 17, 2014Screen Writing For Screen Reading
- April 22, 2014Update: Stryker Rejuvenate and ABGII Lawsuits Progress in New Jersey State Court
- Spring 2014Eli Lilly and Company v. Teva Parenteral Medicines, Inc.
- Spring 2014Generic Launches
- Spring 2014ANDA Litigation Settlements
- Spring 2014Senju Pharmas. Co., Ltd. v. Apotex Inc. (Fed Cir)
- Spring 2014Allergan, Inc. v. Sandoz Inc.
- Spring 2014The Medicines Co. v. Hospira, Inc.
- Spring 2014Apotex, Inc. v. Daiichi Sankyo Co.
- Spring 2014Shire Dev. LLC v. Watson Pharms., Inc.
- Spring 2014Pfizer Inc. et. al v. Teva Pharmaceuticals USA, Inc. et al. (Fed Cir)
- Spring 2014ANDA Approvals
- Spring 2014Warner Chilcott Co., LLC v. Teva Pharms. USA, Inc.
- Spring 2014Classen Immunotherapies, Inc. v. Shionogi, Inc.
- Spring 2014Par Pharms., Inc. v. TWi Pharms., Inc.
- Spring 2014Endo Pharms. Inc. v. Actavis, Inc. (Fed Cir)
- Spring 2014G.D. Searle LLC v. Lupin Pharms, Inc.
- Spring 2014Alcon Research Ltd. v. Barr Labs., Inc.
- Spring 2014New ANDA Cases
- Spring 2014Purdue Pharma L.P. v. Teva Pharms. USA, Inc.
- Spring 2014In re Lamictal Direct Purchaser Antitrust Litigation
- Spring 2014Endo Pharmas. Inc. v. Mylan Pharmas. Inc.
- Spring 2014Takeda Pharma. Co. Ltd. v. Zydus Pharmas. USA, Inc. (Fed Cir)
- Spring 2014GlaxoSmithKline LLC v. Banner Pharmacaps, Inc. (Fed Cir)
- Spring 2014Warner Chilcott Co. LLC v. Lupin Ltd.
- April 11, 2014Calif. Odor Case Stinks For Businesses With CGL Policies
- April 8, 2014Natural-Labeling Litigation: Preparing for the Next Five Years
- April 8, 2014How to Manage Mobile Big Data Legal Risks
